Genetic variation in genes encoding for polymerase ζ subunits associates with breast cancer risk, tumour characteristics and survival.

Abstract:

:Chromosomal instability is a known hallmark of many cancers. DNA polymerases represent a group of enzymes that are involved in the mechanism of chromosomal instability as they have a central function in DNA metabolism. We hypothesized that genetic variation in the polymerase genes may affect gene expression or protein configuration and by that cancer risk and clinical outcome. We selected four genes encoding for the catalytic subunits of the polymerases β, δ, θ and ζ (POLB, POLD1, POLQ and REV3L, respectively) and two associated proteins (MAD2L2 and REV1) because of their previously reported association with chromosomal instability and/or tumorigenesis. We selected potentially functional and most informative tagging single nucleotide polymorphisms (SNPs) for genotyping in a population-based series of 783 Swedish breast cancer (BC) cases and 1562 controls. SNPs that showed a significant association in the Swedish population were additionally genotyped in a Polish population consisting of 506 familial/early onset BC cases and 568 controls. SNPs in all three polymerase ζ subunit genes associated either with BC risk or prognosis. Two SNPs in REV3L and one SNP in MAD2L2 associated with BC risk: rs462779 (multiplicative model: OR 0.79, 95% CI 0.68-0.92), rs3204953 (dominant model: OR 1.28, 95% CI 1.05-1.56) and rs2233004 (recessive model: OR 0.49, 95% CI 0.28-0.86). Homozygous carriers of the minor allele C of the third SNP in REV3L, rs11153292, had significantly worse survival compared to the TT genotype carriers (HR 2.93, 95% CI 1.34-6.44). Minor allele carriers of two REV1 SNPs (rs6761391 and rs3792142) had significantly more often large tumours and tumours with high histological grade and stage. No association was observed for SNPs in POLB, POLQ and POLD1. Altogether, our data suggest a significant role of genetic variation in the polymerase ζ subunit genes regarding the development and progression of BC.

authors

Varadi V,Bevier M,Grzybowska E,Johansson R,Enquist K,Henriksson R,Butkiewicz D,Pamula-Pilat J,Tecza K,Hemminki K,Lenner P,Försti A

doi

10.1007/s10549-011-1460-z

subject

Has Abstract

pub_date

2011-08-01 00:00:00

pages

235-45

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

129

pub_type

杂志文章
  • Effects of autotransplanted lymph node fragments on the lymphatic system in the pig model.

    abstract::Secondary lymphedema often develops after removal of lymph nodes in combination with radiation therapy, in particular in patients with breast cancer, inguinal cancer, cervical cancer and melanoma. No convincing treatment for the prevention and therapy of acquired lymphedema exists so far, therefore we wanted to show t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0367-4

    authors: Blum KS,Hadamitzky C,Gratz KF,Pabst R

    更新日期:2010-02-01 00:00:00

  • A bioassay for antiestrogenic activity--potential utility in drug development and monitoring effective in vivo dosing.

    abstract::Monitoring effective antiestrogenic activity of the triphenylethylenes in patients with breast cancer is usually determined by the duration of response. The pharmacokinetics of toremifene and tamoxifen have been shown to be highly variable but patient specific. In the present study, we developed a method to accurately...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01832356

    authors: DeGregorio M,Wurz G,Emshoff V,Koester S,Minor P,Wiebe V

    更新日期:1992-01-01 00:00:00

  • Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system.

    abstract::Fat necrosis of the breast is increasingly reported and used as a trial endpoint in the treatment of breast cancer with accelerated partial breast irradiation (APBI). Yet, there is no universal toxicity scoring system within the latest version of the Common Terminology Criteria for Adverse Events (CTCAE v4.0). This re...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-013-2611-1

    authors: Russo AL,Taghian AG

    更新日期:2013-07-01 00:00:00

  • Receipt of locoregional therapy among young women with breast cancer.

    abstract::Although younger women with breast cancer have the most to gain from receipt of optimal care, few data are available regarding their receipt of locoregional breast cancer treatments. We identified 317,596 women aged 18-64 who were diagnosed with invasive breast cancer at hospitals reporting to the National Cancer Data...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2156-8

    authors: Freedman RA,Virgo KS,Labadie J,He Y,Partridge AH,Keating NL

    更新日期:2012-10-01 00:00:00

  • Postoperative complications and survival of elderly breast cancer patients: a FOCUS study analysis.

    abstract::Old age is associated with comorbidity and decreased functioning which influences treatment decisions in elderly breast cancer patients. The purpose of this study was to identify risk factors for complications after breast cancer surgery in elderly patients, and to assess mortality in patients with postoperative compl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2462-9

    authors: de Glas NA,Kiderlen M,Bastiaannet E,de Craen AJ,van de Water W,van de Velde CJ,Liefers GJ

    更新日期:2013-04-01 00:00:00

  • Mutation analysis of PALB2 gene in French breast cancer families.

    abstract::Several population-based and family-based studies have demonstrated that germline mutations of the PALB2 gene (Partner and Localizer of BRCA2) are associated with an increased risk of breast cancer. Distinct mutation frequencies and spectrums have been described depending on the population studied. Here we describe th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3625-7

    authors: Damiola F,Schultz I,Barjhoux L,Sornin V,Dondon MG,Eon-Marchais S,Marcou M,GENESIS Study Investigators.,Caron O,Gauthier-Villars M,de Pauw A,Luporsi E,Berthet P,Delnatte C,Bonadona V,Maugard C,Pujol P,Lasset C,Longy M

    更新日期:2015-12-01 00:00:00

  • Body mass index, diet, and exercise: testing possible linkages to breast cancer risk via DNA methylation.

    abstract:PURPOSE:To examine DNA methylation as a mechanism linking diet, physical activity, weight status, and breast cancer risk. METHODS:Insufficiently active women of varying weight status, without a history of cancer, completed a maximal exercise test, clinical measurement of height and weight, and a dietary intake measure...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4573-1

    authors: Gillman AS,Gardiner CK,Koljack CE,Bryan AD

    更新日期:2018-02-01 00:00:00

  • Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells.

    abstract::Aberrant expressions of the neuronal protein synuclein gamma (SNCG) in malignant mammary epithelial cells are strongly associated with the progression of breast cancer. SNCG is not expressed in normal breast tissues but abundantly expressed in a high percentage of invasive and metastatic breast carcinomas. Several stu...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-6938-0

    authors: Inaba S,Li C,Shi YE,Song DQ,Jiang JD,Liu J

    更新日期:2005-11-01 00:00:00

  • Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP).

    abstract:PURPOSE:Estimated glomerular filtration rate (eGFR) is commonly used to calculate carboplatin doses and capping the eGFR may be used to reduce the risk of excessive dosing and toxicity. We sought to retrospectively examine the impact of our carboplatin guidelines on pathological complete response rates (pCR) and toxici...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05868-z

    authors: Howell SJ,Coe F,Wang X,Horsley L,Ekholm M

    更新日期:2020-11-01 00:00:00

  • Early self-reported impairments in arm functioning of primary breast cancer patients predict late side effects of axillary lymph node dissection: results from a population-based cohort study.

    abstract:OBJECTIVES:Improvements in the life expectancy of women with breast cancer raise important questions how to improve quality of life (QoL) for women sustaining complications and side effects of cancer treatment. The presented study examined the prevalence of arm morbidity in a cohort of primary breast cancer patients ov...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9247-3

    authors: Albert US,Koller M,Kopp I,Lorenz W,Schulz KD,Wagner U

    更新日期:2006-12-01 00:00:00

  • Ha-ras rare alleles in breast cancer susceptibility.

    abstract::Over the last several years, evidence has accumulated to support the idea that rare Ha-ras polymorphisms are associated with inherited susceptibility to certain human cancers. A recent epidemiologic study conducted at our institution found a significant association specifically with breast cancer, although the mechani...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00694750

    authors: Conway K,Edmiston S,Fried DB,Hulka BS,Garrett PA,Liu ET

    更新日期:1995-07-01 00:00:00

  • Effect of a multidiscipline mentor-based program, Be Resilient to Breast Cancer (BRBC), on female breast cancer survivors in mainland China-A randomized, controlled, theoretically-derived intervention trial.

    abstract::To reduce the risk of adjustment problems for breast cancer patients in mainland China, we examined the efficacy of a multidiscipline mentor-based program, Be Resilient to Breast Cancer (BRBC), delivered after breast surgery to (a) increase protective factors of social support, hope for the future, etc.; (b) decrease ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-016-3881-1

    authors: Ye ZJ,Liang MZ,Qiu HZ,Liu ML,Hu GY,Zhu YF,Zeng Z,Zhao JJ,Quan XM

    更新日期:2016-08-01 00:00:00

  • PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.

    abstract:PURPOSE:Radiotherapy (RT) constitutes an important part of breast cancer treatment. However, triple negative breast cancers (TNBC) exhibit remarkable resistance to most therapies, including RT. Developing new ways to radiosensitize TNBC cells could result in improved patient outcomes. The M2 isoform of pyruvate kinase ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05376-9

    authors: Zhang L,Bailleul J,Yazal T,Dong K,Sung D,Dao A,Gosa L,Nathanson D,Bhat K,Duhachek-Muggy S,Alli C,Dratver MB,Pajonk F,Vlashi E

    更新日期:2019-11-01 00:00:00

  • Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison.

    abstract:INTRODUCTION:Since older patients with breast cancer are underrepresented in clinical trials, an oncogeriatric approach is advocated to guide treatment decisions. However, the effect on outcomes is unclear. The aim of this study was to compare treatments and outcomes between patients treated in an oncogeriatric and a s...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05860-7

    authors: de Boer AZ,van de Water W,Bastiaannet E,de Glas NA,Kiderlen M,Portielje JEA,Extermann M

    更新日期:2020-11-01 00:00:00

  • Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.

    abstract:PURPOSE:Clinical trials demonstrated adjuvant aromatase inhibitor treatment is superior for decreasing breast cancer recurrence risk over adjuvant tamoxifen treatment as early as 2001. Yet clinical use for adjuvant treatment was not recommended by the American Society of Clinical Oncology until 2004. Aromatase inhibito...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9558-z

    authors: Aiello EJ,Buist DS,Wagner EH,Tuzzio L,Greene SM,Lamerato LE,Field TS,Herrinton LJ,Haque R,Hart G,Bischoff KJ,Geiger AM

    更新日期:2008-02-01 00:00:00

  • Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women.

    abstract::Compelling evidence about the differences in the biology and behavior of invasive breast cancer between African-American (AA) and White-American (WA) women motivate inquiry into comparing the clinicopathology of non-invasive breast cancer (ductal carcinoma in situ, DCIS). AA and WA women diagnosed with their first pri...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1742-5

    authors: Stark A,Stapp R,Raghunathan A,Yan X,Kirchner HL,Griggs J,Newman L,Chitale D,Dick A

    更新日期:2012-01-01 00:00:00

  • MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.

    abstract::Node-positive breast carcinoma is associated with a poor prognosis. Some patients benefit from adjuvant chemotherapy but new treatment modalities should still be developed in order to further increase the cure rate in this patient group. Prognostic factors are needed to define patients for such studies. Here, the prog...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006326513176

    authors: Talvensaari-Mattila A,Pääkkö P,Turpeenniemi-Hujanen T

    更新日期:1999-12-01 00:00:00

  • Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.

    abstract::To investigate the prognostic value of tumor markers, cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) levels at diagnosis of systemic recurrence. After primary treatments of locoregional breast cancers, serum CA 15-3 and/or CEA concentrations were regularly measured, and systemic recurrences were iden...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2695-7

    authors: Lee JS,Park S,Park JM,Cho JH,Kim SI,Park BW

    更新日期:2013-10-01 00:00:00

  • Vascular proliferation is a prognostic factor in breast cancer.

    abstract::Angiogenesis is important for the growth and spread of malignant tumors, and anti-angiogenesis treatment is currently being evaluated for breast cancer and other tumors. Although microvessel density is the most commonly used tissue-based marker of tumor associated angiogenesis, it has significant limitations and has n...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1785-7

    authors: Arnes JB,Stefansson IM,Straume O,Baak JP,Lønning PE,Foulkes WD,Akslen LA

    更新日期:2012-06-01 00:00:00

  • Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.

    abstract::We have compared the effects of the progestin R5020 and the antiprogestin RU486 on the growth of the MCF-7 and T47D breast cancer cell lines. Differences between the two compounds were demonstrated in several parameters. 1. Estradiol was required for the efficient inhibition of cell growth of both lines by R5020 but n...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806133

    authors: Gill PG,Vignon F,Bardon S,Derocq D,Rochefort H

    更新日期:1987-10-01 00:00:00

  • Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.

    abstract::Docetaxel-containing chemotherapy improves disease-free survival (DFS) and overall survival in patients with early stage breast cancer. Bevacizumab improves response rate and DFS in metastatic breast cancer. However, adding antivascular endothelial growth factor therapy to anthracycline-containing chemotherapy may inc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-013-2764-y

    authors: Yardley DA,Hart L,Waterhouse D,Whorf R,Drosick DR,Murphy P,Badarinath S,Daniel BR,Childs BH,Burris H

    更新日期:2013-12-01 00:00:00

  • Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.

    abstract:PURPOSE:Platinum plays an important role in the treatment of triple-negative breast cancer (TNBC) in neoadjuvant and metastatic settings. However, its role in an adjuvant setting remains unclear. METHODS:In this non-inferior randomized phase 2 trial, we randomly assigned 308 chemotherapy-naive patients with histologic...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-020-05648-9

    authors: Du F,Wang W,Wang Y,Li M,Zhu A,Wang J,Cai R,Ma F,Fan Y,Li Q,Zhang P,Todorovic V,Yuan P,Xu B

    更新日期:2020-07-01 00:00:00

  • Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.

    abstract:BACKGROUND:The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses are frequently discordant between the primary tumor and metastatic lesions in metastatic breast cancer. This can have important therapeutic implications. PATIENTS AND METHODS:In all, 541 pati...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05746-8

    authors: Walter V,Fischer C,Deutsch TM,Ersing C,Nees J,Schütz F,Fremd C,Grischke EM,Sinn P,Brucker SY,Schneeweiss A,Hartkopf AD,Wallwiener M

    更新日期:2020-08-01 00:00:00

  • Analysis of breast cancer in young women in the Department of Defense (DOD) database.

    abstract:PURPOSE:Breast tumors from young women under the age of 40 account for approximately 7% of cases and have a poor prognosis independent of established prognostic factors. We evaluated the patient population served by the Military Health System, where a disproportionate number of breast cancer cases in young women are se...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4615-8

    authors: Zimmer AS,Zhu K,Steeg PS,Wu A,Gatti-Mays ME,Soltani S,Perkins JG,Shao S,Brown D,Georg M,Hu H,Shriver CD,Lipkowitz S

    更新日期:2018-04-01 00:00:00

  • Urinary estrogens and estrogen metabolites and mammographic density in premenopausal women.

    abstract::Mammographic density is a strong and independent risk factor for breast cancer and is considered an intermediate marker of risk. The major predictors of premenopausal mammographic density, however, have yet to be fully elucidated. To test the hypothesis that urinary estrogen metabolism profiles are associated with mam...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2240-0

    authors: Bertrand KA,Eliassen AH,Hankinson SE,Gierach GL,Xu X,Rosner B,Ziegler RG,Tamimi RM

    更新日期:2012-11-01 00:00:00

  • Patients' understanding of their own disease and survival potential in patients with metastatic breast cancer.

    abstract:PURPOSE:To investigate the effect of understanding their own disease by patients with metastatic breast cancer on their survival potential after being informed by their physician. PATIENTS AND METHODS:Two hundred and fourteen women with metastatic breast cancer who participated in a multi-institutional, randomized pha...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1023/a:1006483214678

    authors: Okamura H,Yamamoto N,Watanabe T,Katsumata N,Takashima S,Adachi I,Kugaya A,Akechi T,Uchitomi Y

    更新日期:2000-05-01 00:00:00

  • The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer.

    abstract:PURPOSE:Triple-negative breast cancer (TNBC)/basal-like breast cancer (BLBC) is a highly aggressive form of breast cancer. We previously reported that a small molecule agonist ligand for the orphan nuclear receptor estrogen-related receptor beta (ERRβ or ESRRB) has growth inhibitory and anti-mitotic activity in TNBC ce...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05485-5

    authors: Fernandez AI,Geng X,Chaldekas K,Harris B,Duttargi A,Berry VL,Berry DL,Mahajan A,Cavalli LR,Győrffy B,Tan M,Riggins RB

    更新日期:2020-02-01 00:00:00

  • Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.

    abstract:PURPOSE:Homologous recombination (HR)-deficient breast tumors may have genomic alterations that predict response to treatment with PARP inhibitors and other targeted therapies. METHODS:Comprehensive molecular profiles of 4647 breast tumors performed at Caris Life Sciences using 592-gene NGS were reviewed to identify s...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05849-2

    authors: Heeke AL,Xiu J,Elliott A,Korn WM,Lynce F,Pohlmann PR,Isaacs C,Swain SM,Vidal G,Schwartzberg LS,Tan AR

    更新日期:2020-11-01 00:00:00

  • Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting.

    abstract:OBJECTIVES:To validate the newly proposed American Joint Committee on Cancer (AJCC) prognostic staging system for breast cancer. METHODS:Surveillance, epidemiology, and end results (SEER) database (2010-2014) was accessed. Cumulative incidence function was conducted (through assessment of sub-distribution hazard) acco...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4577-x

    authors: Abdel-Rahman O

    更新日期:2018-02-01 00:00:00

  • Association between persistence with mammography screening and stage at diagnosis among elderly women diagnosed with breast cancer.

    abstract::Previous studies on the association between mammography screening and stage at breast cancer (BC) diagnosis have limitations because they did not analyze persistence with mammography screening and did not distinguish screening from diagnostic mammograms. The objective of this study is to determine the association betw...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3204-3

    authors: Vyas A,Madhavan S,Sambamoorthi U

    更新日期:2014-12-01 00:00:00